Latest Biosimilar Stories
Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
- BIO Investor Forum to be held October 7-8 in San Francisco - SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Pfenex Inc.
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced a full agenda
South Korea emerges among the frontrunners in the race to lead the global biosimilars market PHILADEPHIA, Sept.
REDWOOD CITY, Calif., Sept.
An Alliance Of 5 Companies Experienced In Biosimilars Development MANNHEIN, Germany, Sept.
SAN DIEGO, Sept. 19, 2014 /PRNewswire/ -- Pfenex Inc.
Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass.,
The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
- A poem in which the author retracts something said in an earlier poem.